Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) EVP Eric Swayze Sells 7,154 Shares

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) EVP Eric Swayze sold 7,154 shares of the firm’s stock in a transaction that occurred on Thursday, January 16th. The stock was sold at an average price of $32.84, for a total value of $234,937.36. Following the transaction, the executive vice president now owns 45,670 shares in the company, valued at approximately $1,499,802.80. The trade was a 13.54 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Eric Swayze also recently made the following trade(s):

• On Tuesday, November 12th, Eric Swayze sold 1,194 shares of Ionis Pharmaceuticals stock. The shares were sold at an average price of $37.92, for a total value of $45,276.48.

Ionis Pharmaceuticals Stock Performance

Ionis Pharmaceuticals stock opened at $31.43 on Monday. Ionis Pharmaceuticals, Inc. has a twelve month low of $31.40 and a twelve month high of $52.49. The company has a quick ratio of 8.82, a current ratio of 8.91 and a debt-to-equity ratio of 1.86. The company has a market capitalization of $4.96 billion, a P/E ratio of -12.88 and a beta of 0.35. The stock’s 50 day moving average is $35.63 and its 200 day moving average is $41.11.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on IONS. Royal Bank of Canada reiterated an “outperform” rating and set a $70.00 price target on shares of Ionis Pharmaceuticals in a report on Wednesday, January 15th. Needham & Company LLC reiterated a “buy” rating and set a $60.00 target price on shares of Ionis Pharmaceuticals in a report on Friday, December 20th. Guggenheim cut their target price on Ionis Pharmaceuticals from $70.00 to $65.00 and set a “buy” rating on the stock in a research note on Wednesday, October 9th. William Blair reaffirmed an “outperform” rating on shares of Ionis Pharmaceuticals in a research report on Friday, December 20th. Finally, Piper Sandler cut their price objective on Ionis Pharmaceuticals from $65.00 to $62.00 and set an “overweight” rating on the stock in a research report on Thursday, November 14th. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $60.65.

Institutional Investors Weigh In On Ionis Pharmaceuticals

A number of institutional investors have recently modified their holdings of IONS. GAMMA Investing LLC raised its position in shares of Ionis Pharmaceuticals by 83.9% in the 3rd quarter. GAMMA Investing LLC now owns 664 shares of the company’s stock worth $27,000 after purchasing an additional 303 shares during the last quarter. Itau Unibanco Holding S.A. bought a new stake in Ionis Pharmaceuticals during the 2nd quarter valued at about $37,000. Capital Performance Advisors LLP purchased a new position in Ionis Pharmaceuticals in the third quarter worth about $40,000. Prospera Private Wealth LLC bought a new position in shares of Ionis Pharmaceuticals in the third quarter worth approximately $42,000. Finally, Quantbot Technologies LP purchased a new stake in shares of Ionis Pharmaceuticals during the third quarter valued at approximately $51,000. 93.86% of the stock is owned by hedge funds and other institutional investors.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.